Clearside Biomedical stock hits 52-week low at $0.77

Published 09/04/2025, 14:40
Clearside Biomedical stock hits 52-week low at $0.77

Clearside Biomedical Inc . (NASDAQ:CLSD) stock has reached a 52-week low, trading at $0.77, marking a significant downturn for the biopharmaceutical company. According to InvestingPro data, the stock has fallen nearly 12% in the past week alone, with a market capitalization now at approximately $61 million. This latest price level reflects a challenging period for the firm, which specializes in the development of treatments for serious eye diseases. Over the past year, Clearside Biomedical has seen its stock value decrease by 33.95%, with revenue declining by nearly 80%. Despite these challenges, InvestingPro analysis reveals some bright spots, including impressive gross profit margins above 90% and a strong liquidity position with a current ratio of 4.44. The 52-week low serves as a critical indicator for investors monitoring the stock's volatility (Beta: 2.04) and the company's valuation in the highly competitive biotech sector. For deeper insights, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, covering this and 1,400+ other US stocks.

In other recent news, Clearside Biomedical reported a significant revenue beat for the fourth quarter of 2024, with revenue reaching $306,000, surpassing the forecast of $130,140. The earnings per share (EPS) matched expectations at -0.1. Meanwhile, the company is advancing its CLS-AX treatment for wet age-related macular degeneration (AMD (NASDAQ:AMD)) into Phase 3 trials, following successful Phase 2 results and an agreement with the FDA. Analysts from Stifel and JMP Securities have expressed positive outlooks, maintaining a "Buy" rating with a target of $8 and a "Market Outperform" rating with a target of $5, respectively. These developments underscore the company's strategic focus on its innovative dosing regimen, which aims to offer a flexible treatment option. Additionally, Clearside Biomedical concluded 2024 with $20 million in cash, which is expected to fund operations into the fourth quarter of 2025. The company is actively seeking additional capital to support its Phase 3 trials, anticipated to commence in the second half of 2025. Furthermore, Clearside's collaborations, including those with Arctic Vision and ABBV/RGNX, are progressing, with several programs advancing into later trial stages.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.